Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311).
Mitsuya IshikawaTaro ShibataTomoko KataokaMunetaka TakekumaHiroaki KobayashiNobuo YaegashiToyomi Satohnull nullPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
jRCTs031180007.